Are you now using luspatercept as your first choice for anemia management in patients with low-risk MDS otherwise appropriate for EPO initiation, regardless of presence of SF3B1 or ringed sideroblasts?

Since the publication of the COMMANDS trial results, has your approach to treating patients with transfusion dependent low-risk MDS with anemia changed?

• Yes, I am now more likely to consider luspatercept as a first-line treatment option in most patients
• Yes, I am now more likely to consider luspatercept as a first-line treatment option but only in patients not eligible for EPO
• Yes, I am now more likely to consider luspatercept as a first-line treatment option but only in patients with ringed sideroblasts or SF3B1 mutation
• Yes, I am more likely to consider luspatercept for patients who previously failed other treatments
• No, my treatment approach for low-risk MDS with anemia has not changed significantly
• I am still undecided about the potential impact of COMMANDS on my treatment decisions and awaiting more data
• Other